imatinib actavis group 100 mg filmtabletta
actavis group ptc ehf. - imatinib -
imatinib actavis group 200 mg filmtabletta
actavis group ptc ehf. - imatinib -
imatinib actavis group 300 mg filmtabletta
actavis group ptc ehf. - imatinib -
imatinib actavis group 400 mg filmtabletta
actavis group ptc ehf. - imatinib -
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. a hatás az imatinib az eredmény, csontvelő-transzplantáció nem határozták meg. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. a tapasztalatok imatinib a betegek mds/mpd kapcsolódó pdgfr gén újra szabályok nagyon korlátozott. nincs kontrollált vizsgálatok, amelyek klinikai haszon vagy fokozott túlélés ezek a betegségek.
desloratadin actavis 5 mg szájban diszpergálódó tabletta
actavis group ptc ehf. - dezloratadin -
candesartan actavis 4 mg tabletta
actavis group ptc ehf. - candesartan -
candesartan actavis 8 mg tabletta
actavis group ptc ehf. - candesartan -
candesartan actavis 16 mg tabletta
actavis group ptc ehf. - candesartan -
candesartan actavis 32 mg tabletta
actavis group ptc ehf. - candesartan -